ONCOLOGIST[ta] - Search Results

Year	Number of Results
1996	61
1997	55
1998	60
1999	67
2000	97
2001	106
2002	102
2003	86
2004	117
2005	119
2006	141
2007	174
2008	177
2009	159
2010	202
2011	246
2012	235
2013	239
2014	228
2015	278
2016	240
2017	304
2018	390
2019	559
2020	568
2021	462
2022	286
2023	303
2024	221

1

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.

Morganti S, Bychkovsky BL, Poorvu PD, Garrido-Castro AC, Weiss A, Block CC, Partridge AH, Curigliano G, Tung NM, Lin NU, Garber JE, Tolaney SM, Lynce F. Morganti S, et al. Oncologist. 2023 Jul 5;28(7):565-574. doi: 10.1093/oncolo/oyad123. Oncologist. 2023. PMID: 37210568 Free PMC article. Review.

2

Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.

John AO, Ramnath N. John AO, et al. Oncologist. 2023 Sep 7;28(9):752-764. doi: 10.1093/oncolo/oyad125. Oncologist. 2023. PMID: 37338126 Free PMC article. Review.

3

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.

Wang C, Zhao K, Hu S, Dong W, Gong Y, Xie C. Wang C, et al. Oncologist. 2023 Jun 2;28(6):e397-e405. doi: 10.1093/oncolo/oyad111. Oncologist. 2023. PMID: 37116899 Free PMC article. Review.

4

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.

Ramnaraign B, Sartor O. Ramnaraign B, et al. Oncologist. 2023 May 8;28(5):392-401. doi: 10.1093/oncolo/oyac279. Oncologist. 2023. PMID: 36806966 Free PMC article.

5

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.

Muñoz J, Sarosiek S, Castillo JJ. Muñoz J, et al. Oncologist. 2023 Apr 6;28(4):309-318. doi: 10.1093/oncolo/oyac260. Oncologist. 2023. PMID: 36723874 Free PMC article. Review.

6

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.

Fonseca R, Facon T, Hashim M, Nair S, He J, Ammann E, Lam A, Wildgust M, Kumar S. Fonseca R, et al. Oncologist. 2023 May 8;28(5):e263-e269. doi: 10.1093/oncolo/oyad053. Oncologist. 2023. PMID: 37002943 Free PMC article.

7

Waiting for ASCO to "Walk the Walk".

Fojo T. Fojo T. Oncologist. 2023 Nov 2;28(11):921-924. doi: 10.1093/oncolo/oyad256. Oncologist. 2023. PMID: 37774404 Free PMC article.

8

Perspectives on the Treatment of Multiple Myeloma.

Rafae A, van Rhee F, Al Hadidi S. Rafae A, et al. Oncologist. 2024 Mar 4;29(3):200-212. doi: 10.1093/oncolo/oyad306. Oncologist. 2024. PMID: 37995307 Free PMC article. Review.

9

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.

Colombo N, Lorusso D, Monk BJ, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, Zale M, Okpara CE, Barresi G, McKenzie J, Makker V. Colombo N, et al. Oncologist. 2024 Jan 5;29(1):25-35. doi: 10.1093/oncolo/oyad201. Oncologist. 2024. PMID: 37523661 Free PMC article.

10

Highlights of ASCO 2023.

Neugut AI, Bates SE. Neugut AI, et al. Oncologist. 2023 Sep 7;28(9):739-742. doi: 10.1093/oncolo/oyad222. Oncologist. 2023. PMID: 37548435 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

5,732 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

5,732 results

Results by year